Controlling hypertension to the desired target is commonly unsuccessful and requires multi-drug regimen, which can lead to undesirable side effects. Resistant hypertension (RH) is more cumbersome to deal with and has robust morbidity and mortality burden even with current multiple medical options. Herein, we review the literature for the potential role of sodium-glucose cotransporter 2 inhibitors (SGLT2i) as a treatment option for hypertension and RH.

中文翻译：

---

顽固性高血压的药物治疗：钠-葡萄糖协同转运蛋白 2 抑制剂 (SGLT2i) 的作用。

将高血压控制在预期目标通常是不成功的，需要多种药物治疗，这可能会导致不良副作用。即使目前有多种医疗选择，难治性高血压（RH）处理起来也更加麻烦，并且具有沉重的发病率和死亡率负担。在此，我们回顾了钠-葡萄糖协同转运蛋白 2 抑制剂 (SGLT2i) 作为高血压和 RH 治疗选择的潜在作用的文献。